Supply Chain | February 26, 2025
Amgen India investment totals $200 million through 2025
YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
Sarat Kumar has been appointed as CFO of the company and also designated as Key Managerial Personnel with effect from February 21, 2025
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
Collaborates with VisionSpring to conduct eye check-up camps for underprivileged children
the inspection conducted from January 27 to January 31, 2025
The Alathur facility specializes in the production of Cephalosporin antibiotics
Subscribe To Our Newsletter & Stay Updated
_256_384.JPG)
